News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CorMedix (CRMD) Notified of NYSE MKT Listing Deficiency


4/12/2013 9:40:25 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, received a notice from the NYSE MKT on April 5, 2013 indicating that it is below listing standard criteria. In its Form 10-K for the fiscal year ended December 31, 2012. CorMedix reported stockholders’ equity of less than $2 million and did not meet certain of the NYSE MKT continued listing standards as set forth in the NYSE MKT Company Guide.

Read at BioSpace.com

comments powered by Disqus
CorMedix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES